South Korea Tetanus Toxoid Vaccine Market

South Korea Tetanus Toxoid Vaccine Market Summary

As per Transpire Insight Analysis the South Korea Tetanus Toxoid Vaccine Market size is estimated at USD 131.75 Million in 2025 and is anticipated to reach USD 229.78 Million by 2033, growing at a CAGR of 7.20% from 2026 to 2033.

South Korea uses the tetanus toxoid vaccine as part of regular childhood immunizations. It is also given after certain injuries. The shot helps prevent tetanus when a cut or wound is contaminated. Protection is kept up with booster doses given at planned times.

More attention has shifted to adults in recent years. South Korea recommends Td or Tdap booster shots about every 10 years after kids complete their initial series. There are also plans to vaccinate people who missed shots earlier and do not have full records.During the COVID-19 years, giving vaccines became harder. Clinics had to keep services running and arrange missed doses later. Even with those disruptions, routine vaccination still continued.

Overall, the vaccine is used beyond early childhood. Clinicians manage booster schedules for adults, they use Tdap during pregnancy, and they address tetanus risk from wounds. With these routines in place, vaccine buying trends can stay steadier.When use stays steady, income for suppliers can be less erratic. It can also help vaccine makers and distribution partners keep reliable stock for both public and private care sites.

South Korea Tetanus Toxoid Vaccine Market Size & Forecast:

• South Korea Tetanus Toxoid Vaccine Market Size 2025: USD 131.75 Million
• Expected Market Value 2033: USD 229.78 Million
• Forecast CAGR: 7.20%
• Key Profile: GC Biopharma, SK Bioscience, LG Chem, Sanofi, Pfizer, GSK, Merck & Co., Serum Institute of India, Bharat Biotech, CSL Seqirus, Biological E, Bavarian Nordic, Astellas Pharma, Janssen Pharmaceuticals, Takeda Pharmaceutical.

Key Market Insights

• South Korea’s tetanus toxoid vaccine scene is moving toward more regular adult booster doses. Use tied to pregnancy is also rising. Domestic supply plans are getting more reliable for the years 2026 through 2030.
• In South Korea, KDCA rules call for Td or Tdap boosters every 10 years after the childhood series. This means people keep cycling back to vaccination over time.
• Demand is still concentrated in the Seoul capital area. In 2025, that region is a useful demand stand-in because about half of the country’s population lives there.
• Other cities and metro areas are adding purchases little by little. This continues through 2026 to 2030. Access is likely to widen as clinic networks and public health channels expand.
• For products, Tdap is taking the lead. Adult schedules are leaning more toward the combined approach that covers tetanus, diphtheria, and pertussis instead of Td alone.
• Td comes next in size. It stays important because there are already adult booster routes in place. It is also used in wound care related vaccination needs.
• Tdap is expected to grow faster than other options up to 2030. Growth is linked to multiple use cases. This includes pregnancy use, adolescent boosters, adult boosters, and cocooning vaccination.
• By use type, adult booster vaccination is the main application. The KDCA 10-year revaccination rule drives this. There is also a three dose catch up path for those who missed earlier doses.
• The quickest growth is seen in pregnancy related vaccination and family contact vaccination. The reason is that Tdap coverage can extend protection to newborns through people around them.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Tetanus Toxoid Vaccine Market?

Korea uses a set adult boost plan, and that is the main focus. After kids finish their early shots, the KDCA tells adults to get Tdap or Td once every 10 years. If an adult cannot prove past vaccines, clinics often switch to a three shot course. This can mean more repeat visits over time. It also gives hospitals a clearer basis for ordering supplies in a steady way. Tdap is also pushed more in pregnancy cases, and for people who will be around a newborn.

A key drawback is tied to how much Tdap comes from abroad. In 2025, GC Biopharma said the Tdap vaccines sold in Korea depend fully on imports. That means plans can swing if there are delays at makers or if quality checks fail. In 2024, some GSK Boostrix lots were put on pause due to packaging issues. It was a quick example of how a quality matter can change what clinics can get. A Transpire Insight look at regional purchase notices and timing pointed in the same direction. The risk in day to day rollout still centers on where the supply is concentrated.

The best path would be to make Tdap in Korea. GC Biopharma got approval in March 2025 to run Phase 1 and Phase 2 tests for GC3111B in adults ages 19 to 64. They expect to wrap up by 2026. The plan covers the full chain, from starting materials to the finished vaccine. If the schedule holds, it could reduce reliance on imports and make procurement less shaky.

What Has the Impact of Artificial Intelligence Been on the South Korea Tetanus Toxoid Vaccine Market?

AI is already changing vaccine work. Most of the shift is in planning and scheduling, not in lab work. What gets attention first is digital stock tracking. It also includes demand checks and the clinic calendar.In Korea, the immunization program reviews what suppliers say they will make. It also compares those plans with what will be brought in. That is done against what officials expect to need. After that, delivery teams still have to follow rules on storage and cold chain handling.

When teams use AI forecasting, they can reuse those records to look for changes in need by region. It can also help flag when refills may be required. In some cases, it can give an earlier heads up when supplies are nearing the low point.Other models can use past vaccination records to guess future Tdap demand. They may sort by age group and the timing of booster shots. They can also factor in pregnancy related notes. They may look at how often people attend each clinic. This matters because KDCA expects adult booster doses every 10 years. Those fixed intervals help form groups that can be planned sooner.

Electronic immunization records can also help. Simple reminders can catch people who missed doses. That can reduce some manual time spent on scheduling.The earliest benefits may show up as less waste in the supply chain. There may also be fewer urgent orders near deadlines. Cold chain handling can improve too. This is not mainly about faster vaccine production. The main issue is that data lives in many separate systems. Public purchasing, private clinic records, maker stock reports, and patient records do not always link together in a single usable setup. For that reason, AI is often used as an extra tool. Its value depends on how full the data is and on how well the pieces can be joined.

Key Market Trends

• KDCA keeps pushing for Tdap or Td shots every 10 years for adults. This adds more doses each year. It also builds on what people already get as kids.
• Tdap has become more important for two reasons. More pregnant people are getting protection. Newborn-contact groups also need coverage. That link makes adult vaccines matter more.
• GC Biopharma started Phase 1/2 work for GC3111B in 2025. The goal is to make enough Tdap inside the country.
• Government planners are also changing how they plan supplies. They now lean more on what makers say they can ship. They watch import plans too. They hold extra stock. They also check cold-chain handling after recent shortages.
• GSK moved Boostrix through SK bioscience starting in 2021. That helped keep steady sales routes for imported Tdap.
• Sanofi later added Adacel through SK bioscience in 2024. This put more pressure on the imported Tdap market. It also increased direct competition.
• In 2024, a Boostrix lot was paused. That showed how fast quality checks can affect supply. It also led to more focus on monitoring products as well as continuity.
• Digital vaccine records are spreading. Procurement teams are using forecasts more often. This is the opening room for AI tools. The tools can help plan booster timing and manage inventory.
• GC Biopharma had set up domestic TD capacity earlier. Now that work is moving toward Tdap. This points to deeper local production across 2025 and 2026.

South Korea Tetanus Toxoid Vaccine Market Segmentation

By Vaccine Type : 

Tetanus toxoid vaccines are used to lower the chance of getting tetanus in both children and adults. Families get them as part of regular childhood care. People also get booster shots later. Some are given during pregnancy checkups. They may be used after certain wounds. They are also used for work settings where the risk is higher.Tdap has taken on added weight in recent years. Vaccine programs now pay more attention to protection for teens, older adults, and pregnant mothers. TD is still used too. It shows up in booster plans and in care after injuries. DTaP and DT mostly fit the pediatric schedule.Using combo vaccines can make the timing easier to manage. They can reduce how many shots a child needs overall. The choice of product depends on the person’s age, the record of prior doses, what is going on at the clinic visit, and the rules used in that country for immunizations.

Booster doses for adults keep pushing demand. These schedules bring people back for the next round of vaccination. Tdap given in pregnancy also supports wider use among expectant mothers. In parallel, vaccines for children help clinics and institutions keep their purchasing steady.More attention is now going toward vaccines made in the same country. GC Biopharma is working on Tdap, aiming to help strengthen local supply. What gets bought will be shaped by options for imported products, including cost and access, and also by what new domestic products may be offered later.

By Age Group : 

Infants and kids still matter most, since tetanus prevention is built into routine shots given during childhood. When a child gets older, the plan shifts. Teens get Tdap to add more coverage. This helps move from the first round of pediatric vaccines to later booster protection. Adults are also a key target. Booster doses are expected to keep protection going once childhood effects fade. Older people may need special attention too, especially when past vaccine dates are missing or when it is hard to judge when boosters are due.

Pregnancy has become even more important. Getting Tdap during pregnancy helps protect the baby from pertussis and lowers tetanus risk around delivery. Health workers are another group to watch. Their job can expose them to disease, so vaccination may depend on the setting and on medical advice. In many clinics, age-based planning helps staff choose the right vaccine based on what someone already received and what is needed now. Better electronic records can also help find missed boosters and keep schedules steadier across different ages.

By Application : 

Routine vaccination helps keep demand in a steady range. It uses the normal timing for children and for grown ups.Some injuries can raise the need. A dirty wound or a wound with high risk might call for a tetanus dose. The choice depends on what shots someone had before and what the wound is like.Shots in pregnancy now matter more. A Tdap shot during pregnancy can help guard the baby soon after birth. In that first stretch, the newborn has the weakest protection.

Vaccines at work can add more demand as well. Certain staff members can face higher exposure. Their need for shots may depend on the tasks they do.In emergencies, prophylaxis can lead to quick requests. Hospitals, clinics, and public health offices may have to act fast.Travel related vaccines make up a smaller part of the total. They come from pre trip visits and from the rules for the place being visited.Military health programs can add planned buying. They usually move through set health systems.Public programs and local clinic rules also shape the number of doses used. Adult booster shots can bring more repeat use too. This can occur beyond the usual childhood schedule.

By End User : 

Hospitals are still key for the people who use care. They manage immunization as part of urgent visits, wound care, and daily clinical work. They also support mothers and provide other services where vaccines are used in the care plan.Immunization centers serve people who keep to fixed vaccine dates. They can also run booster programs for adults. Some patients go to regular clinics instead. Clinics can be easier to reach, and they often help with shots tied to pregnancy.Public health offices support plans that the government backs. They also help organize community vaccine events. As more care sites start giving shots, pharmacies may end up taking a larger share in the overall setup.

Health agencies in the government guide major purchasing choices. They set the national rules for immunization, plan how vaccines are stocked, and run public vaccine drives. Public sites, like hospitals, need a steady supply and they must use cold-chain steps so vaccines stay effective.Private clinics may expand access by offering appointment times that work better for patients. They may also take on more adult vaccination work. In the end, purchasing by institutions will likely keep following government actions, clinical advice, patient counts, and which vaccines are offered across care settings.

By Distribution Channel : 

Public buying still matters for vaccine delivery. Federal agencies and state teams line up purchases by calendar. They also have to watch the flow of goods more closely.Pharmacies in hospitals support care for people who are already on site. That can include care for admitted patients. It also covers urgent visits. Some patients get vaccines during prenatal appointments. Others receive them when being treated for cuts or wounds.Retail pharmacies offer a separate route. They serve people who meet eligibility rules set in each area. In many settings, the pharmacist can give the shot if the law and workflow allow it.Wholesalers connect makers with care facilities. They send supplies to hospitals and clinics. They also serve other provider groups. Their work helps keep products on hand across multiple areas.

Not all sales follow the same path. Sometimes a supplier ships directly to large organizations. These options can work well for major customer groups. They can also match special purchase plans.Vaccine storage needs care, not shortcuts. Cold-chain rules guide how items are kept, moved, and logged. Staff must plan stock while shipments are in transit, so shortages do not happen.Teams use digital systems more often for purchasing. Good tools can show inventory status sooner than older methods. They can also reduce the chance of running short. Orders can be set with more care.When production grows closer to home, partnerships can shift. New local output can bring new distribution contacts. Even then, the products still move through usual healthcare routes.

What are the Key Use Cases Driving the South Korea Tetanus Toxoid Vaccine Market?

Routine immunization stays the main reason these products are used. It covers the planned shots for children and the Td or Tdap booster given about every 10 years for teens and adults. Vaccine buyers include hospitals, vaccination sites, clinics, and public health centers. They stock supplies to keep up with the yearly schedule and to handle the repeat booster visits.

Another steady demand comes from wound care. This is mostly seen in hospitals and emergency clinics when people have dirty wounds or serious injuries. There is also a maternal program that supports Tdap use in pregnancy. In practice, the shot is advised in weeks 27 to 36 so the baby is protected close to delivery.

Work rules and travel needs add smaller value but they are growing. Many workplaces run health programs, and travel clinics give advice and shots before trips. There is also room in emergency care. In that setting, hospitals decide on vaccination based on how bad the wound is and what shots the person had before.

Which Regions are Driving the South Korea Tetanus Toxoid Vaccine Market Growth?

The Seoul Capital Area drives the largest demand. It makes up about half of the reachable vaccine need when you look at where people live, not on audited revenue by region. In this area, hospitals are close together. There are big vaccination centers and many public health sites. Specialist clinics also help cover routine care, shots for mothers, and booster needs for adults. GC Biopharma, SK bioscience, GSK, and Sanofi have long standing ties with hospitals and clinics across the metro area. Local vaccine development also brings extra supply. This mix of population, healthcare access, and buying patterns should keep the Seoul Capital Area in front through 2033. Still, exact regional market share figures are not available.

Yeongnam looks different in how demand forms. It has major cities and a strong base of industrial work. Hospitals and work related healthcare services play a key role. Ongoing manufacturing and factory activity leads to repeat vaccination needs. At the same time, people receive routine immunizations through hospitals in the region and through public health facilities. Healthcare systems here are stable, and procurement paths are already set up. That means revenue can hold steady even with

out the same population pull seen near Seoul. Busan, Ulsan, and nearby areas have enough clinical capacity to keep steady vaccine purchasing across the forecast.

Chungcheong looks like the quickest area to focus on. The main reason is the rise in population in Chungnam and Chungbuk. Sejong stands out the most, with a big increase in residents. Looking ahead, Sejong was expected to keep growing a lot up to 2040. Chungnam and Chungbuk were also forecast to show steady population growth over the long run. With more people in these places, more healthcare services will be needed.As public buildings expand and more homes are built, access to care can improve. That shift can help vaccination numbers grow from 2026 through 2033.For new players and investors, this means there are clear targets. They can work with local clinics in the region. They can also look at public health purchasing. Hospital groups and networks may be another path as demand rises.

Who are the Key Players in the South Korea Tetanus Toxoid Vaccine Market and How Do They Compete?

Competition is still led by a small group of vaccine makers. A small set of Korean distribution firms also controls much of the channel. In this space, securing supply is the first test. Next comes a wide product list. Regulatory strength matters a lot. Another key point is whether production can be done inside Korea. Cost matters as well. Still, it does not pull the decisions most of the time.SK bioscience has grown by taking on GSK’s Boostrix sales work since 2021. It adds Sanofi’s Adacel in 2024. This setup gives imported Tdap brands a clearer route into adult vaccine sales in Korea.

GC Biopharma is going a different way. It is working on GC3111B in Korea. The company plans to begin Phase 1/2 for adults aged 19 to 64. GC Biopharma wants to close development by 2026.GSK depends on Boostrix. It also uses a distribution deal that links GSK’s vaccine lineup with SK bioscience’s local sales team. The aim is broader access for adult vaccination.Sanofi relies on Adacel. It also grows local distribution through SK bioscience. With this arrangement, Korean providers get another imported Tdap option for adult vaccines.

GC Biopharma builds its position by doing the work fully in Korea for GC3111B. That means it targets key components and also makes the final product. It also looks toward WHO prequalification. It wants to supply other markets beyond Korea.SK bioscience stands out with its own distribution setup. It also has several global vaccine ties. Because of that, it can bring in imported products with less delay. It can also grow its wider vaccine portfolio.

Company List

• GC Biopharma
• SK Bioscience
• LG Chem
• Sanofi
• Pfizer
• GSK
• Merck & Co.
• Serum Institute of India
• Bharat Biotech
• CSL Seqirus
• Biological E
• Bavarian Nordic
• Astellas Pharma
• Janssen Pharmaceuticals
• Takeda Pharmaceutical 

Recent Development News

In January 2025, SK bioscience and Sanofi expanded their strategic partnership covering Sanofi vaccines distributed in South Korea, including the Tdap product Adacel. The expanded collaboration reinforced domestic distribution access for an established tetanus-containing vaccine and supported broader coverage across public and private vaccination channels. 

Source: https://www.skbioscience.com/

In March 2025, GC Biopharma received approval to begin Phase 1/2 clinical development of GC3111B, an adult Tdap vaccine. The development marks a domestic technology investment aimed at reducing South Korea’s reliance on imported Tdap vaccines and strengthening future local supply.

Source: https://www.gcbiopharma.com/

What Strategic Insights Define the Future of the South Korea Tetanus Toxoid Vaccine Market?

In the next 5 to 7 years, the market may lean more toward a booster-driven setup. This is tied to South Korea’s plan for Td and Tdap over a 10 year span, plus options for people who missed earlier doses. The main change is that protection is no longer only aimed at early childhood. Instead, more doses are planned across adult and teen years. That tends to make purchasing patterns more even for clinics and hospitals.

There is also a less obvious issue to watch. Supply is not evenly spread. The KDCA tracks how makers plan production and what will be brought in. It also keeps Tdap reserves on hand, since problems in one place can disrupt the national schedule. If the market leans too hard on a small group of suppliers, revenue could drop fast. This could happen even if vaccination demand stays about the same.

At the same time, there is a new opening. Building Tdap manufacturing inside the country could help. The key would be using technology that can meet public buying needs. It could also lower reliance on imports. Companies should look closely at local manufacturing ties, use more than one supply channel, and set longer buy agreements early. That may help before limits in capacity become clearer.

South Korea Tetanus Toxoid Vaccine Market Report Segmentation

By Vaccine Type

• Tetanus Toxoid Vaccine
• Td Vaccine
• Tdap Vaccine
• DTaP Vaccine
• DT Vaccine
• Combination Vaccines
• Pediatric Tetanus Vaccines
• Adult Tetanus Vaccines

By Age Group

• Infants
• Children
• Adolescents
• Adults
• Elderly
• Pregnant Women
• Healthcare Workers

By Application

• Routine Immunization
• Wound Management
• Maternal Immunization
• Travel Vaccination
• Occupational Vaccination
• Emergency Prophylaxis
• Military Vaccination

By End User

• Hospitals
• Vaccination Centers
• Clinics
• Public Health Centers
• Pharmacies
• Government Health Agencies

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Government Procurement
• Vaccination Programs
• Wholesalers
• Direct Sales